Sign Out
Locally advanced non-small cell lung cancer (NSCLC): IMFINZI (durvalumab) is indicated for the treatment of patients with locally advanced, unresectable NSCLC whose disease has not progressed following platinum-based chemoradiation therapy.
IMFINZI in combination with tremelimumab and platinum-based chemotherapy is indicated for treatment of adults with metastatic NSCLC with no sensitising EGFR mutations or ALK positive mutations.
Small Cell Lung Cancer (SCLC): IMFINZI in combination with etoposide and either carboplatin or cisplatin is indicated for the first-line treatment of adult patients with extensive-stage small cell lung cancer (ES-SCLC).
Biliary Tract Cancer (BTC): IMFINZI in combination with gemcitabine and cisplatin is indicated for treatment of adults with unresectable or metastatic biliary tract cancer (BTC).
Hepatocellular Carcinoma (HCC): IMFINZI in combination with tremelimumab is indicated for treatment of adults with advanced or unresectable hepatocellular carcinoma (HCC).
Lanjutkan dengan Google